Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Deferred Tax Liability: 2020

  • BridgeBio Pharma's Non-Current Deferred Tax Liability was N/A to $1.1 million in Q4 2020 from the same period last year, while for Dec 2020 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2020, which is N/A change from last year.
  • As of Q4 2020, BridgeBio Pharma's Non-Current Deferred Tax Liability stood at $1.1 million.
  • BridgeBio Pharma's 5-year Non-Current Deferred Tax Liability high stood at $1.1 million for Q4 2020, and its period low was $1.1 million during Q4 2020.
  • Over the past 1 years, BridgeBio Pharma's median Non-Current Deferred Tax Liability value was $1.1 million (recorded in 2020), while the average stood at $1.1 million.